Thai H. Ho, MD, PhD, discusses the role of TKI monotherapy in the first-line treatment of patients with metastatic renal cell carcinoma.
Thai H. Ho, MD, PhD
Advertisement
Articles by Thai H. Ho, MD, PhD
Thai H. Ho, MD, PhD, discusses frontline treatment regimens in metastatic renal cell carcinoma.
Thai H. Ho, MD, PhD, assistant professor of medicine, Mayo Clinic, discusses the management of immune-related adverse events in the treatment of kidney cancer.
Thai H. Ho, MD, PhD, assistant professor of medicine, Mayo Clinic, discusses common molecular subtype and phenotype alterations in the epigenetic pathway that are used to predict response to treatment.
Advertisement
Latest Updated Articles
Dr. Ho on How Molecular Subtypes Affect SequencingPublished: March 2nd 2018 | Updated:
Dr. Ho on Managing Immune-Related AEs in Kidney CancerPublished: September 11th 2018 | Updated:
Dr. Ho on Frontline Treatment Regimens in mRCCPublished: November 4th 2019 | Updated:
Dr. Ho on First-Line TKI Monotherapy in mRCCPublished: November 12th 2019 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5